PART I Overview We are a clinical-stage biopharmaceutical company aiming to transform the lives of patients by e stablishing a new class of medicines that engage intracellular targets that have long been considered inaccessible . Through proprietary, versatile and modular approaches, we are advancing a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases, among others. In 2026, we expect to progress our ENTR-601-44 and ENTR...
Q2 FY2026 — expected 2026-08-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001689375-26-000011 | EDGAR | 111K words |
| 2025-02-27 | 2024-12-31 | 0001689375-25-000011 | EDGAR | — |
| 2024-03-13 | 2023-12-31 | 0001689375-24-000016 | EDGAR | — |
| 2023-03-06 | 2022-12-31 | 0001689375-23-000019 | EDGAR | — |
| 2022-03-15 | 2021-12-31 | 0001558370-22-003614 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-06 | 2025-09-30 | 0001689375-25-000050 | EDGAR | 75K words |
| 2025-08-06 | 2025-06-30 | 0001689375-25-000043 | EDGAR | — |
| 2025-05-08 | 2025-03-31 | 0001689375-25-000024 | EDGAR | — |
| 2024-11-05 | 2024-09-30 | 0001689375-24-000063 | EDGAR | — |
| 2024-08-13 | 2024-06-30 | 0001689375-24-000047 | EDGAR | — |
| 2024-05-07 | 2024-03-31 | 0001689375-24-000027 | EDGAR | — |
| 2023-11-07 | 2023-09-30 | 0001689375-23-000074 | EDGAR | — |
| 2023-08-08 | 2023-06-30 | 0001689375-23-000055 | EDGAR | — |
| 2023-05-10 | 2023-03-31 | 0001689375-23-000039 | EDGAR | — |
| 2022-11-07 | 2022-09-30 | 0001689375-22-000045 | EDGAR | — |
| 2022-08-11 | 2022-06-30 | 0001689375-22-000013 | EDGAR | — |
| 2022-05-12 | 2022-03-31 | 0001689375-22-000004 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-26 | 0001689375-26-000009 | EDGAR | 3K words |
| 2026-01-08 | 0001689375-26-000003 | EDGAR | — |
| 2025-11-06 | 0001689375-25-000049 | EDGAR | — |
| 2025-08-06 | 0001689375-25-000041 | EDGAR | — |
| 2025-06-11 | 0001104659-25-058536 | EDGAR | — |
| 2025-06-03 | 0001689375-25-000027 | EDGAR | — |
| 2025-05-08 | 0001689375-25-000022 | EDGAR | — |
| 2025-04-29 | 0001104659-25-041204 | EDGAR | — |
| 2025-03-24 | 0001689375-25-000018 | EDGAR | — |
| 2025-02-27 | 0001689375-25-000009 | EDGAR | — |
76 total filings indexed. 49 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001689375 |
| Ticker | TRDA |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.entradatx.com |
| Listed | 2021-10-29 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report